IL162376A0 - Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-ir) - Google Patents
Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-ir)Info
- Publication number
- IL162376A0 IL162376A0 IL16237602A IL16237602A IL162376A0 IL 162376 A0 IL162376 A0 IL 162376A0 IL 16237602 A IL16237602 A IL 16237602A IL 16237602 A IL16237602 A IL 16237602A IL 162376 A0 IL162376 A0 IL 162376A0
- Authority
- IL
- Israel
- Prior art keywords
- igf
- modulators
- insulin
- receptor
- growth factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104140A SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Novel Compounds |
PCT/SE2002/002221 WO2003048133A1 (en) | 2001-12-07 | 2002-12-03 | Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162376A0 true IL162376A0 (en) | 2005-11-20 |
Family
ID=20286257
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16237602A IL162376A0 (en) | 2001-12-07 | 2002-12-03 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-ir) |
IL162376A IL162376A (en) | 2001-12-07 | 2004-06-06 | Pyrimidine derivatives wherein a nitrogen heteroatom is attached at positions 2 and 4 thereof, process for their preparation, pharmaceutical compositions containing them and use of such pyrimidine derivatives in the manufacture of medicaments and as medicaments for modulating insulin-like growth factor-1 receptor activity in a patient |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL162376A IL162376A (en) | 2001-12-07 | 2004-06-06 | Pyrimidine derivatives wherein a nitrogen heteroatom is attached at positions 2 and 4 thereof, process for their preparation, pharmaceutical compositions containing them and use of such pyrimidine derivatives in the manufacture of medicaments and as medicaments for modulating insulin-like growth factor-1 receptor activity in a patient |
Country Status (33)
Country | Link |
---|---|
US (3) | US7521453B2 (xx) |
EP (1) | EP1456182B1 (xx) |
JP (1) | JP4347051B2 (xx) |
KR (1) | KR100930558B1 (xx) |
CN (1) | CN1289486C (xx) |
AR (1) | AR037736A1 (xx) |
AT (1) | ATE425150T1 (xx) |
AU (1) | AU2002365864B2 (xx) |
BR (1) | BR0214605A (xx) |
CA (1) | CA2467838C (xx) |
CO (1) | CO5590919A2 (xx) |
CY (1) | CY1109101T1 (xx) |
DE (1) | DE60231542D1 (xx) |
DK (1) | DK1456182T3 (xx) |
EG (1) | EG24930A (xx) |
ES (1) | ES2323125T3 (xx) |
HK (1) | HK1067631A1 (xx) |
HU (1) | HUP0401855A3 (xx) |
IL (2) | IL162376A0 (xx) |
IS (1) | IS7294A (xx) |
MX (1) | MXPA04005347A (xx) |
MY (1) | MY135705A (xx) |
NO (1) | NO327502B1 (xx) |
NZ (1) | NZ533130A (xx) |
PL (1) | PL369528A1 (xx) |
PT (1) | PT1456182E (xx) |
RU (1) | RU2317291C2 (xx) |
SE (1) | SE0104140D0 (xx) |
SI (1) | SI1456182T1 (xx) |
TW (1) | TWI324152B (xx) |
UA (1) | UA78259C2 (xx) |
WO (1) | WO2003048133A1 (xx) |
ZA (1) | ZA200404223B (xx) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
RS53109B (en) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
DE602004032446D1 (de) * | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
KR100872204B1 (ko) * | 2003-10-15 | 2008-12-09 | 오에스아이 파마슈티컬스, 인코포레이티드 | 이미다조피라진 티로신 키나제 억제제 |
DE602004022187D1 (de) | 2003-10-17 | 2009-09-03 | Astrazeneca Ab | 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
EA200601687A1 (ru) | 2004-03-12 | 2007-04-27 | Аналитикон С.А. | Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1 |
US7973061B2 (en) * | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
MY143225A (en) | 2004-04-02 | 2011-03-31 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
DE102004022897A1 (de) * | 2004-05-10 | 2005-12-08 | Bayer Cropscience Ag | Azinyl-imidazoazine |
MY139689A (en) | 2004-07-20 | 2009-10-30 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
ATE519759T1 (de) * | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
WO2006082392A1 (en) * | 2005-02-04 | 2006-08-10 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
ES2308731T3 (es) * | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | Compuestos quimicos. |
GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
JP2008540335A (ja) * | 2005-04-27 | 2008-11-20 | アストラゼネカ・アクチエボラーグ | ピラゾリル・ピリミジン誘導体の疼痛治療における使用 |
WO2006123113A2 (en) * | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
CN101304731B (zh) | 2005-08-24 | 2012-06-20 | 惠氏公司 | 醋酸苯卓昔芬制剂及其生产方法 |
DK1926996T3 (da) | 2005-09-20 | 2012-01-23 | Osi Pharmaceuticals Llc | Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere |
PT1945631E (pt) * | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
TWI427084B (zh) * | 2006-06-09 | 2014-02-21 | Novartis Ag | 穩定化之類胰島素生長因子多肽 |
AU2007257701A1 (en) * | 2006-06-15 | 2007-12-21 | Boehringer Ingelheim International Gmbh | 2-anilino-4-aminoalkyleneaminopyrimidines |
MX2008016523A (es) * | 2006-06-30 | 2009-01-19 | Astrazeneca Ab | Derivados de pirimidina utiles en el tratamiento de cancer. |
CA2656290A1 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
WO2008129255A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
US20100137398A1 (en) * | 2007-05-04 | 2010-06-03 | Novartis Ag | Use of hdac inhibitors for the treatment of gastrointestinal cancers |
UA99459C2 (xx) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | ПОХІДНІ 9-(ПІРАЗОЛ-3-ІЛ)-9H-ПУРИН-2-АМІНУ І 3-(ПІРАЗОЛ-3-ІЛ)-3H-ІМІДАЗО$4,5-b]ПІРИДИН-5-АМІНУ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ РАКУ$ПРОИЗВОДНЫЕ 9-(ПИРАЗОЛ-3-ИЛ)-9H-ПУРИН-2-АМИНА И 3-(ПИРАЗОЛ-3-ИЛ)-3H-ИМИДАЗО$4,5-b]ПИРИДИН-5-АМИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА |
US8178091B2 (en) | 2007-05-21 | 2012-05-15 | University Of Washington | Compositions and methods for the treatment of respiratory disorders |
WO2009019518A1 (en) * | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
EP2283020B8 (en) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
AR072085A1 (es) * | 2008-06-11 | 2010-08-04 | Astrazeneca Ab | Compuestos triciclicos, metodos para su preparacion, composicion farma-ceutica que los comprende y su uso en el tratamiento de enfermedades me-diadas por la actividad de las proteinas quinasas |
DE102008041214A1 (de) | 2008-08-13 | 2010-02-18 | Bayer Cropscience Ag | N-substituierte Azinylakyl-azincarboxamide und deren Analoge |
BRPI0919488A2 (pt) * | 2008-09-30 | 2015-12-01 | Astrazeneca Ab | composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2547204A2 (de) | 2010-03-18 | 2013-01-23 | Bayer Intellectual Property GmbH | Aryl- und hetarylsulfonamide als wirkstoffe gegen abiotischen pflanzenstress |
CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
US8546443B2 (en) * | 2010-12-21 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Benzylic oxindole pyrimidines |
JP2014510265A (ja) | 2011-02-02 | 2014-04-24 | アムジェン インコーポレイテッド | Igf−1rの阻害に関する方法および組成物 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
US9096691B2 (en) | 2011-04-13 | 2015-08-04 | Eastman Chemical Company | Cellulose ester optical films |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | CANCER THERAPY |
EP3044593A4 (en) | 2013-09-09 | 2017-05-17 | Triact Therapeutics, Inc. | Cancer therapy |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
CN115124475B (zh) * | 2022-07-11 | 2023-11-10 | 贵阳学院 | 一种嘧啶衍生物及其制备方法和用途 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1417402A (en) * | 1972-03-30 | 1975-12-10 | Boots Co Ltd | Pharmacologically active anilinobenzothiazoles |
DE2426180A1 (de) * | 1974-05-29 | 1975-12-18 | Bayer Ag | Verfahren zum faerben von polyurethankunststoffen |
US4485284A (en) * | 1982-01-11 | 1984-11-27 | Advanced Moisture Technology, Inc. | Apparatus and process for microwave moisture analysis |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CA2104053C (en) * | 1992-08-31 | 1999-04-13 | Miguel A. Cacho | Automated fluid bed process |
WO1997009325A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DK0970369T3 (da) * | 1997-03-27 | 2002-01-28 | Glatt Gmbh | Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget ..... |
US6247246B1 (en) * | 1998-05-27 | 2001-06-19 | Denver Instrument Company | Microwave moisture analyzer: apparatus and method |
ATE342892T1 (de) | 1998-08-29 | 2006-11-15 | Astrazeneca Ab | Pyrimidine verbindungen |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
ATE316781T1 (de) | 1999-09-24 | 2006-02-15 | Janssen Pharmaceutica Nv | Antivirale feste dispersionen |
US6455525B1 (en) * | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03002294A (es) * | 2000-09-15 | 2005-09-08 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP1345922B1 (en) * | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA04001088A (es) * | 2001-08-03 | 2004-05-20 | Vertex Pharma | Derivados de pirazol como inhibidores de cinasa y uso de los mismos. |
US6750239B2 (en) * | 2001-08-03 | 2004-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
US6747461B2 (en) * | 2001-10-25 | 2004-06-08 | Pioneer Hi-Bred International, Inc. | Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
ES2354824T3 (es) * | 2004-11-04 | 2011-03-18 | Vertex Pharmaceuticals, Inc. | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas. |
ES2308731T3 (es) * | 2005-02-16 | 2008-12-01 | Astrazeneca Ab | Compuestos quimicos. |
RU2427578C2 (ru) * | 2005-11-03 | 2011-08-27 | Вертекс Фармасьютикалз Инкорпорейтед | Аминопиримидины в качестве ингибиторов киназ |
MX2008016523A (es) * | 2006-06-30 | 2009-01-19 | Astrazeneca Ab | Derivados de pirimidina utiles en el tratamiento de cancer. |
TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
-
2001
- 2001-12-07 SE SE0104140A patent/SE0104140D0/xx unknown
-
2002
- 2002-03-12 UA UA20040705367A patent/UA78259C2/uk unknown
- 2002-12-02 TW TW091134937A patent/TWI324152B/zh not_active IP Right Cessation
- 2002-12-03 EP EP02791165A patent/EP1456182B1/en not_active Expired - Lifetime
- 2002-12-03 HU HU0401855A patent/HUP0401855A3/hu unknown
- 2002-12-03 JP JP2003549325A patent/JP4347051B2/ja not_active Expired - Fee Related
- 2002-12-03 IL IL16237602A patent/IL162376A0/xx unknown
- 2002-12-03 DK DK02791165T patent/DK1456182T3/da active
- 2002-12-03 CA CA2467838A patent/CA2467838C/en not_active Expired - Fee Related
- 2002-12-03 AU AU2002365864A patent/AU2002365864B2/en not_active Ceased
- 2002-12-03 DE DE60231542T patent/DE60231542D1/de not_active Expired - Lifetime
- 2002-12-03 KR KR1020047008612A patent/KR100930558B1/ko not_active IP Right Cessation
- 2002-12-03 BR BR0214605-3A patent/BR0214605A/pt not_active IP Right Cessation
- 2002-12-03 MX MXPA04005347A patent/MXPA04005347A/es active IP Right Grant
- 2002-12-03 SI SI200230824T patent/SI1456182T1/sl unknown
- 2002-12-03 PT PT02791165T patent/PT1456182E/pt unknown
- 2002-12-03 PL PL02369528A patent/PL369528A1/xx not_active Application Discontinuation
- 2002-12-03 CN CNB02827802XA patent/CN1289486C/zh not_active Expired - Fee Related
- 2002-12-03 ES ES02791165T patent/ES2323125T3/es not_active Expired - Lifetime
- 2002-12-03 AT AT02791165T patent/ATE425150T1/de active
- 2002-12-03 NZ NZ533130A patent/NZ533130A/en not_active IP Right Cessation
- 2002-12-03 RU RU2004121029/04A patent/RU2317291C2/ru not_active IP Right Cessation
- 2002-12-03 WO PCT/SE2002/002221 patent/WO2003048133A1/en active Application Filing
- 2002-12-03 US US10/497,744 patent/US7521453B2/en not_active Expired - Fee Related
- 2002-12-04 MY MYPI20024549A patent/MY135705A/en unknown
- 2002-12-06 AR ARP020104747A patent/AR037736A1/es unknown
-
2004
- 2004-05-28 ZA ZA200404223A patent/ZA200404223B/en unknown
- 2004-06-03 CO CO04052141A patent/CO5590919A2/es not_active Application Discontinuation
- 2004-06-03 IS IS7294A patent/IS7294A/is unknown
- 2004-06-06 EG EGNA2004000039 patent/EG24930A/xx active
- 2004-06-06 IL IL162376A patent/IL162376A/en not_active IP Right Cessation
- 2004-07-06 NO NO20042872A patent/NO327502B1/no not_active IP Right Cessation
-
2005
- 2005-01-06 HK HK05100089.7A patent/HK1067631A1/xx not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/359,541 patent/US20090131463A1/en not_active Abandoned
- 2009-05-25 CY CY20091100558T patent/CY1109101T1/el unknown
-
2011
- 2011-12-07 US US13/313,097 patent/US20120095011A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162376A0 (en) | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-ir) | |
HK1072059A1 (en) | Antibodies to insulin-like growth factor I receptor | |
EG24848A (en) | Preparation of aminopyrimidine compounds | |
SI2570414T1 (sl) | Heterociklične aromatske spojine uporabne kot sekretagogi rastnega hormona | |
AU2002346491A1 (en) | Crystalline compositions for controlling blood glucose | |
AU2002342653A1 (en) | Modified growth hormone | |
PL375979A1 (en) | Pyrazole derivatives as transforming growth factor (tgf) inhibitors | |
AU2002361960A1 (en) | Growth promoter composition for animals | |
AU2002212497A1 (en) | Motion compensation of images | |
AU2003269885A1 (en) | Antisense modulation of g protein-coupled receptor kinase 6 expression | |
AU2002222753A1 (en) | Compositions for inducing secretion of insulin-like growth factor-1 | |
AU3269399A (en) | Transforming growth factor (tfg) beta superfamily antagonists | |
AU2002359160A1 (en) | PIPAZOLO (1,5-a) PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR | |
AU2002248484A1 (en) | Muscle-polymer constructs for bone tissue engineering | |
AU2002344813A1 (en) | Methods for synthesizing substituted pyrimidines | |
AU2002255997A1 (en) | Substrate composition for multispectural imaging | |
AU2002247732A1 (en) | Substituted pyrimidinone derivatives as ligands of integrin receptors | |
AU2002229728A1 (en) | Resorbable bone cement containing active agents | |
AU2002345085A1 (en) | Substituted $g(g)-lactone compounds serving as nmda antagonists | |
AU2002310672A1 (en) | Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors | |
AU2002238859A1 (en) | Stable crystals of pyrrole compound | |
AU2002334988A1 (en) | Gastrointestinal chemosensory receptors | |
AU2002313179A1 (en) | Processes for preparation of heterocyclic compounds | |
GB0111083D0 (en) | Formation of small crystals | |
GB0127380D0 (en) | Formation of small crystals |